Conventional chemotherapeutics and targeted antineoplastic agents have been developed
based on the simplistic notion that cancer constitutes a cell-autonomous genetic or …

The role of fibronectin (FN) in tumorigenesis and malignant progression has been highly
controversial. Cancerous FN plays a tumor-suppressive role, whereas it is pro-metastatic …

We describe the development of OncoFAP, an ultra-high-affinity ligand of fibroblast
activation protein (FAP) for targeting applications with pan-tumoral potential. OncoFAP binds …

Antibody-cytokine fusion proteins (immunocytokine) exert a potent anti-cancer effect; indeed,
they target the immunosuppressive tumor microenvironment (TME) due to a specific anti …

The remarkable clinical success of immune-checkpoint inhibitors for the treatment of a
growing number of cancer types has sparked interest in the discovery of novel forms of …

Antibody-cytokine fusion proteins represent a novel class of biopharmaceuticals, with the
potential to increase the therapeutic index of cytokine 'payloads' and to promote leukocyte …

Fibronectin is an extracellular matrix protein with pivotal physiological and pathological
functions in development and adulthood. Alternative splicing of the precursor mRNA …

Cytokines have long been used for therapeutic applications in cancer patients. Substantial
side effects and unfavorable pharmacokinetics limit their application and may prevent dose …

During cancer progression, the extracellular matrix (ECM) undergoes dramatic changes,
which promote cancer cell migration and invasion. In the remodeled tumor ECM, the …

Tumor-associated neovasculature is a critical therapeutic target; however, despite significant
progress made in the clinical efficacy of anti-vessel drugs, the effect of these agents remains …